Ligand Pharmaceuticals Incorporated - Common Stock (LGND)
202.35
+11.97 (6.29%)
NASDAQ · Last Trade: Nov 6th, 11:29 AM EST
Detailed Quote
Previous Close
190.38
Open
196.00
Bid
202.96
Ask
206.72
Day's Range
186.96 - 210.00
52 Week Range
93.58 - 194.44
Volume
109,297
Market Cap
3.37B
PE Ratio (TTM)
-50.09
EPS (TTM)
-4.0
Dividend & Yield
N/A (N/A)
1 Month Average Volume
148,987
Chart
About Ligand Pharmaceuticals Incorporated - Common Stock (LGND)
Ligand Pharmaceuticals is a biopharmaceutical company that focuses on the development of innovative therapies and treatments by leveraging its proprietary drug discovery technologies and a diverse portfolio of drug candidates. The company primarily collaborates with other pharmaceutical and biotechnology firms to discover and advance new medications, particularly in areas such as oncology, cardiovascular diseases, and metabolic disorders. Through its unique platform, Ligand aims to enhance drug efficacy and streamline the development process, contributing to the advancement of healthcare solutions that improve patient outcomes. Read More
San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025. This significant milestone comes on the heels of a robust third-quarter 2025 earnings report that dramatically exceeded analyst expectations,
Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter for 2025. The company's performance was marked by significant growth across its Innovative Medicine and MedTech segments, showcasing the strategic success of its
• Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra’s AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to invest $10 million in an equity private placement and an additional $20 million in a secured subordinated promissory note convertible to prepaid revenue share • Medtronic and Orchestra BioMed expand strategic collaboration to provide pathway for development of AVIM therapy-enabled leadless pacemakers
The launch triggered a $5 million milestone payment to Ligand, which also holds a 56% stake in Pelthos and is eligible for royalties and additional commercial milestones.
Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel.
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2024 financial results before the opening of the U.S. financial markets on Thursday, February 27, 2025. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update.
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025 at 2:40 p.m. Eastern Time.
